New cholesterol-lowering ingredient
This article was originally published in The Tan Sheet
Executive Summary
Next Pharmaceuticals announces Dec. 5 its patented heart-health ingredient Flavoxine is clinically shown to increase HDL-cholesterol while "significantly reducing" LDL-cholesterol and triglycerides. The double-blind, placebo-controlled clinical trial included 80 subjects. "The active compounds from the plants used have been studied extensively and therefore Flavoxine does not have the risks frequently associated with new synthetic compounds," says Next Pharmaceuticals President and CEO Bob Garrison. The Carlsbad, Calif.-based company says Flavoxine is a blend of a proprietary extract of Phellodendron amurense and a patented extract of orange peel containing polymethoxylated flavones. The firm says the ingredient will be available to consumer product manufacturers in January...